Onward Medical: A 5x ARC-EX Ramp Meets a Springtime Binary

H1 revenue up 250%, a fresh BlackRock credit line, and an Empower BP readout that arrives before the next AGM season

ONWD.BR · Earnings Call · 2026-09-09

The Ramp Is No Longer a Promise

Onward Medical spent years as a story stock awaiting a product. The first half of 2026 is the quarter where the arithmetic started to look like a business. Management reported 159 ARC-EX systems sold or supplied via paid evaluation in H1 — more than a five-fold increase year over year — with 89 of those landing in Q2 alone. Put differently, “we delivered nearly as many ARC-EX units in the second quarter of this year as we did in all of 2025” — Sean Sciara, Chief Medical Officer (CMO) · 2026-09-09. Revenue of EUR 4.2 million, up 250%, is small in absolute terms but the direction is unambiguous. The crucial new vector is home use. Through the clinic channel, ARC-EX was a capital-equipment sale to rehab centers; the home version converts a single institutional relationship into a recurring stream of patient-level orders. “We are selling more units for home use than clinic units, and that is a trend that started in the first quarter, it continued in the second quarter, and we expect it to continue” — Dave Marver, Chief Executive Officer (CEO) · 2026-09-09. That migration matters because it changes the reimbursement conversation from facility budgeting to patient access — and the company says 90%+ of VA patients who take the three-month paid evaluation convert to purchase. Geographically, the footprint is broadening: 130+ US clinics, 150+ worldwide, with sales into seven European countries and a first non-US, non-Europe market launched. Sean Sciara estimates the US footprint at 35–40% of the facilities that manage spinal cord injury patients after only six quarters of selling — a striking penetration curve for a brand-new therapy.

The Capital Structure Just Got Rebuilt

The financing is arguably the most consequential “what changed” of the half. Onward raised EUR 40.6 million in April, including a EUR 25 million anchor from EQT Life Sciences, and — more interestingly — swapped lenders. BlackRock replaced Runway Growth with an up-to-EUR 50 million facility, EUR 20 million drawn at close, which was used to retire the old existing loan outright. Only the BlackRock facility remains, with additional tranches tied to business milestones rather than the calendar. Management was explicit that it prefers equity capital to debt, reserving the facility as a bridge to higher-valuation raises rather than a funding crutch. The result: EUR 81.5 million of cash at June-end, up from EUR 68.1 million at the start of the year, and “our cash runway now extends into Q1 2028” — Dave Marver, Chief Executive Officer (CEO) · 2026-09-09.

The Spring Binary and a New Indication

The clinical calendar is where the real asymmetry sits. Empower BP, the ARC-IM pivotal study targeting blood-pressure instability after spinal cord injury, now has 22 participants enrolled across 14 active US and Canadian sites, with European sites coming. Management expects to reach the interim-analysis sample size by year-end and to report top-line results in spring 2027, with regulatory approval targeted for end-2028 and a commercial launch in early 2029. What is genuinely new is EIGER, a feasibility study for the mobility indication — the founding thesis of the company — which completed its first implant. It is grant-funded, run at Swiss institutions, and enrols up to 12 patients. The design logic is subtle and worth flagging:

After a person has spinal cord injury, they lose muscle mass, they lose coordination and proprioception. The thesis here is that if we intervene early, within six weeks of the injury, before that muscle atrophy occurs, then in fact, the mobility therapy will be that much more effective.
Dave Marver, Chief Executive Officer (CEO) · 2026-09-09

That sub-acute enrollment rationale, plus two additional ARC-BCI implants and a further Parkinson's blood-pressure patient, means three ARC platforms are now advancing simultaneously — a pipeline story operating mostly on grant money rather than the P&L.

What Hasn’t Changed — and the Reconciliation

Strip away the momentum and the cash math is still sobering: EUR 26.3 million of operating expenses, a EUR 23.3 million operating loss, a EUR 24.7 million net loss, and no profitability timeline. Onward “don't issue guidance here because the commercialization is still fairly early” — Dave Marver, Chief Executive Officer (CEO) · 2026-09-09, and management flagged that as capital equipment, ARC-EX should show some second-half seasonality rather than a straight-line extrapolation of Q2. The NASDAQ listing remains filed but parked — NASDAQ conditions described as “poised and ready” without a supportive tape for large-cap med-tech. Reimbursement is the swing factor: veterans can access the device today, but the broader US market awaits a CMS coding decision expected in Q4, supplemented by a case-by-case insurance navigation service launched in July. Is this company riding a wave? Somewhat. The market's 90-day advancers are dominated by clinical-catalyst biotech names — open label extension, Phase 1 study, dose-escalation readouts — while the 90-day decliners are heavily weighted toward data-center and AI-infrastructure themes. Onward's spring 2027 readout sits squarely inside that emerging clinical-catalyst preference, and its Breakthrough Device designation keeps the FDA dialogue frequent. But make no mistake: EIGER, Empower BP, ARC-BCI and the VA hub rollout are company-unique narratives, not sector boilerplate. The stock is riding its own data, not the market's mood. The bet here is simple. If the ARC-EX ramp keeps compounding and Empower BP clears its interim, Onward transitions from a cash-burning neurotech pioneer to a two-product platform before its runway ends. If either stalls, the EUR 81.5 million clock is the whole story.